Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 217 results for withdrawal

  1. Adrenal insufficiency: identification and management (NG243)

    This guideline covers identifying and managing adrenal insufficiency (hypoadrenalism) in babies, children, young people and adults. It aims to improve the treatment of primary, secondary and tertiary adrenal insufficiency, and the prevention and management of adrenal crisis.

  2. Generalised anxiety disorder and panic disorder in adults: management (CG113)

    This guideline covers the care and treatment of people aged 18 and over with generalised anxiety disorder (chronic anxiety) or panic disorder (with or without agoraphobia or panic attacks). It aims to help people achieve complete relief of symptoms (remission), which is associated with better functioning and a lower likelihood of relapse.

  3. Withdrawal interventions for gabapentinoids: What are the most clinically and cost-effective strategies or interventions to aid withdrawal of gabapentinoids?

    Question Withdrawal interventions for gabapentinoids: What are the most clinically and cost-effective strategies or interventions to aid...

  4. Multicomponent withdrawal interventions: What are the key components of an effective multicomponent intervention to support dose reduction during withdrawal of opioids?

    Multicomponent withdrawal interventions: What are the key components of an effective multicomponent intervention to support dose...

  5. Multiple sclerosis in adults: management (NG220)

    This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.

  6. Acupuncture to support withdrawal from opioids: What is the clinical and cost effectiveness of acupuncture (including electroacupuncture) as an adjunct to aid withdrawal from opioids?

    Recommendation ID NG215/09 Question Acupuncture to support withdrawal from opioids: What is the clinical and cost effectiveness of...

  7. Falls: assessment and prevention in older people and in people 50 and over at higher risk (NG249)

    This guideline covers assessing risk of falling and interventions to prevent falls in all people aged 65 and over, and people aged 50 to 64 who are at higher risk of falls. It aims to reduce the risk and incidence of falls, and the associated distress, pain, injury, loss of confidence, loss of independence and mortality.

  8. Combined oral contraception: nomegestrol/estradiol (Zoely) (ESNM28)

    Summary of the evidence on nomegestrol/estradiol (Zoely) for use as combined oral contraception to inform local NHS planning and decision-making

  9. Cognitive behavioural therapy (CBT) to support withdrawal from benzodiazepines: What is the most effective model of CBT, including timing of CBT, to support withdrawal from benzodiazepines?

    (CBT) to support withdrawal from benzodiazepines: What is the most effective model of CBT, including timing of CBT, to support...

  10. Coexisting severe mental illness (psychosis) and substance misuse: assessment and management in healthcare settings (CG120)

    This guideline covers assessing and managing people aged 14 years and over with coexisting severe mental illness (psychosis) and substance misuse. It aims to help healthcare professionals guide people with psychosis with coexisting substance misuse to stabilise, reduce or stop their substance misuse, to improve treatment adherence and outcomes, and to enhance their lives.

  11. Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NG193)

    This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is pain with no clear underlying cause, or pain (or its impact) that is out of proportion to any observable injury or disease.

  12. Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31)

    This guideline covers recognising, assessing, diagnosing and treating obsessive-compulsive disorder and body dysmorphic disorder in adults, young people and children (aged 8 years and older). It aims to improve the diagnosis and treatment of obsessive-compulsive disorder and body dysmorphic disorder. It includes recommendations on how families and carers may be able to support people with either of these conditions, and how they can get support for themselves.

  13. Peripheral arterial disease: diagnosis and management (CG147)

    This guideline covers diagnosing and managing peripheral arterial disease (PAD) in people aged 18 and over. Rapid changes in diagnostic methods, endovascular treatments and vascular services associated with new specialties in surgery and interventional radiology have resulted in considerable uncertainty and variation in practice. This guideline aims to resolve that uncertainty and variation.

  14. Converting to a medicine with a different half‑life to aid withdrawal: What is the clinical and cost effectiveness of converting to medicines with a longer half‑life to aid withdrawal from benzodiazepines or antidepressants?

    half‑life to aid withdrawal: What is the clinical and cost effectiveness of converting to medicines with a longer half‑life to aid...

  15. Borderline personality disorder: recognition and management (CG78)

    This guideline covers recognising and managing borderline personality disorder. It aims to help people with borderline personality disorder to manage feelings of distress, anxiety, worthlessness and anger, and to maintain stable and close relationships with others.